In vitro method for the diagnosis and/or prognosis of multiple sclerosis
OwnerÓscar Fernández Fernández, José Ramón Montero Martín-Caloto +6inventors
InventorsÓscar Fernández Fernández, José Ramón Montero Martín-Caloto, José Pavía Molina, Francisco Javier Barón López, Begoña Oliver Martos, Isaac Hurtado Guerrero, Pedro Jesús Serrano Castro, Ana Alonso Torres
Life of this patent
Estimating the term…
Abstract
The present invention refers to an in vitro method for the diagnosis and/or prognosis of multiple sclerosis.
Claims14
In vitro method for the diagnosis and/or prognosis of multiple sclerosis (MS) in a subject, which comprises assessing the concentration level of sIFNAR2 in a biological sample obtained from the subject in combination with the obtention of a magnetic resonance imaging (MRI) to assess the presence/absence of dissemination in space (MRI_DS) and/or dissemination in time (MRI_DT), wherein the identification of a lower level of SIFNAR2 as compared with a pre-established threshold level, and the presence of MRI_DS and/or MRI_DT, are indications that the subject is suffering from MS.
In vitro method, according to any of the previous claims, further comprising the assessment of visual evoked potential (VEP) values.
In vitro method, according to any of the previous claims, further comprising the assessment of the presence or absence of oligoclonal IgG bands (BOC_IgG) in CSF.
In vitro method, according to any of the previous claims, which further comprises processing the concentration level of sIFNAR2, the information obtained from MRI images regarding the presence of MRI_DS and/or MRI_DT, VEP values and information regarding the presence of BOC_IgG in CSF in order to define a risk score, wherein if a deviation or variation of the risk score value is identified, as compared with a reference value, this is indicative that the patient is suffering from MS.
In vitro method, according to any of the previous claims, wherein the biological sample is a biological fluid selected from blood, plasma, serum, cerebrospinal fluid, urine or tears.
In vitro method, according to any of the previous claims, wherein the determination of SIFNAR2 concentration level is carried out by means of an immunoassay, preferably by a technique selected from:
- immunoblot, enzyme-linked immunosorbent assay (ELISA), linear immunoassay (LIA), radioimmunoassay (RIA), immunofluorescence, x-map, protein chips or aptamer-based ELISA, or any technique for the determination of SIFNAR2 concentration level in a biological sample.
In vitro method, according to any of the previous claims, further comprising:
- a. Receiving by a computer program the concentration level of sIFNAR2, information regarding the presence of MRI_DS and/or MRI_DT, VEP values and information regarding the presence of BOC_IgG in CSF.
- b. Processing the information received according to the step a) for finding substantial variations or deviations with respect to the information obtained from a healthy subject, and
- c. Providing an output through a terminal display when a variation or deviation is found which indicates that the subject might be suffering from MS.
In vitro use of sIFNAR2, in combination with MRI measured variables MRI_DS and/or MRI_DT, for the diagnosis and/or prognosis of MS.
Kit-of-parts comprising reagents for assessing the concentration level of sIFNAR2 in combination with MRI to assess the presence/absence of MRI_DS and/or MRI_DT.
Dependencies are inferred from the claim text.